AiM’s breakthrough technology enables surgeons to perform precise neurosurgical procedures directly within an MRI – addressing intraoperative shift and eliminating the need to move patients between operating rooms and imaging suites. The Company’s groundbreaking neurosurgery system leverages real-time intraoperative MRI coupled with robotic guidance to ensure precise placement of neurostimulation leads for Parkinson’s disease patients. AiM’s cutting-edge robotic surgery platform also extends to a wide range of cranial procedures including biopsy, tumor ablation and targeted intracranial delivery of novel therapeutics. This integration offers to make procedures faster, safer and consistently more accurate while reducing patient risk and healthcare costs.
With an initial close in June 2025, the Series A totaled $8.1 million including $3.75 million in notes converted into equity. The financing round attracted a broad base of world-class investors, with significant investment from institutions including IQ Capital, 1540 Ventures and Worcester Polytechnic Institute (WPI); brain cancer impact investors such as the Sontag Innovation Fund (subsidiary of the Sontag Foundation) and Cancer Research Horizons; and prominent angel investor groups including New York Angels (NYA), Harvard Business School Alumni Angels (HBSAA), SWAN Impact Network, Angel Star Ventures and Keiretsu Forum. To date, AiM has raised over $11.3 million in investment, further bolstered by significant federal grant support for the underlying technology.
Gregory Fischer, co-founder and CEO of AiM, said:
“This investment marks the beginning of the next chapter for AiM as we prepare to bring our transformative technology to patients. With first patient enrollment on the horizon, we are eager to demonstrate the profound clinical and commercial impact of AiM’s platform – not only in Parkinson’s disease but across a broad spectrum of cranial procedures including tumor biopsy, cancer and epilepsy ablation, and targeted intracranial drug delivery that will support the burgeoning field of stem cell and gene therapy.”
Alex Wilson, Partner at IQ Capital, said:
“AiM is advancing neurosurgery with a novel robotic platform that integrates seamlessly into existing workflows and provides surgeons with real-time imaging to achieve safer, more precise, and more consistent outcomes for patients. We’re excited to support the company as it moves toward first-in-human trials and clinical adoption.”
Phil Masterson, Associate Director of Ventures, Cancer Research Horizons, said:
“We are delighted to welcome AiM Medical Robotics to the Cancer Research Horizons portfolio. Its surgical robotic system has exciting potential in oncology, from brain tumour biopsy to the delivery of novel therapeutics, including cell and gene therapies and we look forward to enabling further development and validation of the technology in a brain cancer setting. This targeted investment strengthens our continued mission to deliver real impact to patients with cancer worldwide.”
The Series A proceeds will fund AiM’s first-in-human clinical study, expand strategic partnerships and accelerate product development and regulatory milestones.
About AiM Medical Robotics
AiM Medical Robotics is a privately held medical device company based in Worcester, MA, developing next-generation MRI-compatible robotics for neurosurgery. AiM’s compact and portable robotic surgery platform integrates actuated instrument alignment into existing clinical workflows while enabling continuous, real-time visualization during surgery. Looking ahead, AiM plans to harness the power of artificial intelligence to enhance its robotic platform, creating an intelligent surgical ecosystem that can learn from real-world data, optimize workflows, and provide surgeons with predictive insights in real time. By combining advanced intelligent robotics with intraoperative imaging, AiM seeks to unlock a new era of accessible, faster, safer, and more precise brain surgery. The Company’s initial target market – DBS neurostimulator lead placement for conditions Parkinson’s disease, epilepsy, essential tremor, dystonia, and severe OCD – represents an estimated $7.9 billion opportunity.
To learn more about AiM Medical Robotics and its neurosurgical robotics platform, visit https://www.aimmedicalrobotics.com/ and follow on LinkedIn.
About Cancer Research Horizons
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research. It brings together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. It focuses on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.
To date, it has played an instrumental role in forming over 90 start-ups. It has helped bring 14 cancer drugs to market, born out of Cancer Research UK's pioneering research. Through these drugs, it has enabled in excess of 6 million courses of treatment for cancer patients across the world.
With access to Cancer Research UK's network of 4,000 exceptional researchers, and £400m of annual research spend, it is a powerful partner in the fight to conquer cancer. By uniting its commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, data licensing and collaboration, spin-out creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny it makes goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered.
For more information and to get in touch with the team, visit cancerresearchhorizons.com.